Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 17,105 matching trials from the live ClinicalTrials.gov search.

Filters: Philadelphia, Pennsylvania Clear all

Conditions: Obstructive Sleep Apnea
Interventions: Inspire therapy, No intervention; Device · Other
Lead sponsor: Inspire Medical Systems, Inc.; Industry
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 53
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 43 more

Conditions: Healthy Volunteers, Hepatitis C Virus
Interventions: RO5024048; Drug
Lead sponsor: Pharmasset; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more

Conditions: HIV Infections
Interventions: Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 49
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 33 more

Conditions: Breast Carcinoma
Interventions: Computed Tomography, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography; Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions: BE1116, FFP; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more

Conditions: Autoimmune Pulmonary Alveolar Proteinosis
Interventions: Molgramostim, Placebo, Molgramostim Open-label; Drug
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more

Conditions: Esophageal Stricture
Interventions: GIE Medical ProTractX3 TTS DCB, Control; Combination Product · Other
Lead sponsor: GIE Medical; Industry
Eligibility: 22 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 34
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 29 more

Conditions: Pulmonary Disease, Chronic Obstructive, Asthma
Interventions: BI 1744CL; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 22
States / cities: Birmingham, Alabama • Lakewood, California • Denver, Colorado + 17 more

Conditions: Homocystinuria
Interventions: Pegtibatinase, Placebo; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Brain Metastases From Breast Cancer
Interventions: PET/CT Imaging; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: temsirolimus, temozolomide, irinotecan hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 23
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 18 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 34
States / cities: Sheffield, Alabama • Lincoln, California • Newport Beach, California + 31 more

Conditions: Craniocerebral Trauma, Stroke, Intracranial Hemorrhages
Interventions: Early cranioplasty, Standard-of-care cranioplasty; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type B Aortic Dissection
Interventions: TEVAR, Guideline directed medical therapy and surveillance of dissection; Procedure · Other
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more

Conditions: Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions: Sirolimus, MMF or Azathioprine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 20 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Madera, California • San Francisco, California • Boston, Massachusetts + 2 more

Conditions: HIV Infections
Interventions: Doravirine 100 Mg, Integrase strand transfer inhibitors, Tenofovir alafenamide/emtricitabine, tenofovir disproxil fumarate/emtricitabine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation
Interventions: THERMOCOOL® SMARTTOUCH™ Catheter; Device
Lead sponsor: Biosense Webster, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • Stanford, California • Orlando, Florida + 16 more

Conditions: Cystic Fibrosis, Oxidative Stress, Inflammation
Interventions: finely ground flaxseed powder; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: SAR156597, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more

Conditions: Genetic Testing, BRCA1/2
Interventions: Salvia sample, Questionnaires, Buccal swab sample; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 25 Years and older · Female only
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more

Conditions: Breast Cancer
Interventions: Hydroxychloroquine (HCQ), Gedatolisib; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Function, Incentive Spirometry, Patient Adherence, Lung Resection, Thoracic Surgery
Interventions: Adherence to digital incentive spirometer in the postop period after major chest surgery.; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Cherry Hill, New Jersey • Berwyn, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Ascites
Interventions: Alfapump; Device
Lead sponsor: Sequana Medical N.V.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Worcester, Massachusetts + 9 more

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 65
States / cities: Los Angeles, California • San Diego, California • Tarzana, California + 53 more

Search by objective public record fields.

Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer

Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

Timing Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation

Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Flaxseed Modulates Inflammation and Oxidative Stress in CF

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")

Digital Incentive Spirometry Adherence

Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)